DDInter178 DDInter1825
Bendamustine is a nitrogen mustard drug indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophilic alkyl groups that covalently bond to other molecules. Through this function as an alkylating agent, bendamustine causes intra- and inter-strand crosslinks between DNA bases resulting in cell death. It is active against both active and quiescent cells, although the exact mechanism of action is unknown.
Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant to methotrexate. Besides rheumatoid arthritis, tofacitinib has also been studied in clinical trials for the prevention of organ transplant rejection, and is currently under investigation for the treatment of psoriasis. Known adverse effects include nausea and headache as well as more serious immunologic and hematological adverse effects. Tofacitinib is marketed under the brand name Xeljanz by Pfizer.
Tofacitinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Modafinil
Tofacitinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc gluconate
Tofacitinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Esomeprazole
Tofacitinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fostamatinib
Tofacitinib {u} may lead to a major life threatening interaction when taken with {v} Brexucabtagene autoleucel
Tofacitinib {u} may lead to a major life threatening interaction when taken with {v} Fingolimod
Tofacitinib may cause a minor interaction that can limit clinical effects when taken with Modafinil
Tofacitinib may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate
Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Esomeprazole
Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Tofacitinib may lead to a major life threatening interaction when taken with Brexucabtagene autoleucel
Tofacitinib may lead to a major life threatening interaction when taken with Fingolimod